Item 8.01. Other Events.

On August 23, 2022, BeiGene, Ltd. ("BeiGene") announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental biologics license application for tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press release titled "BeiGene Announces Acceptance of 11th Regulatory
                          Submission for PD-1 Inhibitor Tislelizumab in China" issued by BeiGene,
                          Ltd. on August 23, 2022

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses